𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester

✍ Scribed by Ursula Salge; Peter Kilian; Kurt Neumann; Hans-Peter Elsässer; Klaus Havemann; Hans-Heinrich Heidtmann


Publisher
John Wiley and Sons
Year
1990
Tongue
French
Weight
944 KB
Volume
45
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Three cell lines of squamous‐cell carcinoma and 3 of large‐cell carcinoma origin were investigated for the expression of differentiation markers and functional parameters (proliferation, morphology, cornified envelope formation, involucrin staining, transglutaminase activity, adhesiveness and migration) under normal cell culture conditions and after treatment with the tumor promoter phorbol‐12‐myristate‐13‐acetate (PMA). Although all original tumors had been described as poorly differentiated by histological grading, we found significant heterogeneity in the expression of differentiation markers in cell culture. A systematic grading of the cell lines became possible only after PMA stimulation. PMA generally increased expression of differentiation markers in cell lines of comparably low grades of differentiation, as indicated by dose‐dependent inhibition of proliferation and cloning efficiency, induction of squamous markers, and decreased adhesiveness and cell motility. In contrast, cell lines of apparently higher differentiation by these criteria showed little response to PMA. The results presented show that the assessment of differentiation capacity by comparison of differentiation markers under normal cell culture and PMA‐stimulated conditions in established NSCLC cell lines allows for a refined cell culture grading, which might advance the classification and characterization of such cell lines which, otherwise, appear to be very heterogeneous. It may also help to correlate cellular functions with various states of differentiation in vitro.


📜 SIMILAR VOLUMES


Establishment of a human non-small cell
✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m

Control of proteinase expression by phor
✍ Marcus Schuermann; Robert Jäger; Ursula Salge; Gundula Risse-Hackl; Klaus Havema 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 289 KB 👁 2 views

Activation of protein kinase C- (PKC) and Fos/Jun-dependent signal transduction pathways are thought to be major effects of oncogene action in different tumor systems including human non-small-cell lung carcinoma (NSCLC). We have previously shown that the phorbol ester analogue phorbol-myristate-ace

DT-diaphorase as a determinant of sensit
✍ Kazuo Kasahara; Kazuhiko Shibata; Takuma Bando; Yuka Numata; Masaki Fujimura; Ta 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 510 KB

We have reported the establishment of a mitomycin-C (MMC)resistant non-small-cell lung-cancer cell line, PC-9/MC4. As determined by an MlT assay, this resistant cell line was found to be 4 times more sensitive to adriamycin (ADM) than was the parental PC-9. There were no significant differences in s

Effects of bombesin on human small cell
✍ Helen Kado-Fong; Bernard Malfroy 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

The effects of bombesin on three human small cell lung carcinoma cell (SCLC) lines (NCI-H69, NCI-H128, and NCI-H345) have been examined and compared to the effects of the peptide on the mouse fibroblast cell line Swiss 3T3, and the rat pituitary tumor cell line GH3W5. While all three SCLC lines expr

Induction of tubulin by docetaxel is ass
✍ Jinghua Tsai Chang; Gee-Chen Chang; Jiunn-Liang Ko; Hung-Ya Liao; Hsin-Ju Liu; C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 408 KB 👁 1 views

Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell